Famous Patents
The first commercial microwave oven was nearly 6 feet tall and weighed in at 750 pounds.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183370 | Process for the preparation of abacavir Process for removal of the amino protective group of a N-acylated {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-cyclopent-2-enyl}methanol of formula (II) where R═H or a (C1-C4)-alkyl, using an inorganic base in a mixture of water an... | 05/22/2012 |
| 8097723 | Process for the preparation of abacavir Process for the preparation of abacavir, or its salts or its solvates comprising the step of reacting a compound (IV) where R1 is a (C1-C4)-alkyl radical with anhydrous hydrochloric acid/(C1-C6)-alcohol, and the... | 01/17/2012 |
| 8058430 | Biologically active aphrocallistin compounds The subject invention provides novel compositions of biologically active compounds which can advantageously be used in blocking cellular proliferation and/or treatment of cancer. Exemplified are: ... | 11/15/2011 |
| 7834181 | Small-molecule Hsp90 inhibitors Hsp90 inhibitors are provided having the formula: with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and... | 11/16/2010 |
| 7790884 | Acylaminopiperidine compound To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like. An acylaminop... | 09/07/2010 |
| 7601835 | Preparation of famciclovir and other purine derivatives Purine derivatives of formula I, substituted at the 9-position, are prepared from a chloro substituted purine starting material, first making an alkyl substitution at the 9-position, then forming the desired esterified side chain, reducing this and hydrogenating the... | 10/13/2009 |
| 7557209 | Process for the preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol The present invention relates to a process for preparing a chloropurine compound of formula (I) ... | 07/07/2009 |
| 7473780 | Drying process for preparing crystalline solid famciclovir The present invention provides a drying process for preparing crystalline solid famciclovir form I comprising the steps of: i) preparing a wet crystalline form of famciclovir; ii) drying the wet crystalline form of famciclovir at a temperature of below 50° C. until... | 01/06/2009 |
| 7456282 | 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same The present invention relates to a new compound of 2-amino-9-(2-substituted ethyl)purine and an effective method for preparing 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurin (famciclovir) using the same. The 2-amino-9-(2-substituted ethyl)purine according to t... | 11/25/2008 |
| 7439359 | Small molecule compositions for binding to hsp90 Structural differences in binding pockets of members of the HSP90 family can be exploited to achieve differential degradation of kinases and other signaling proteins through the use of designed small molecules which interact with the N-terminal binding pocket with a... | 10/21/2008 |
| 7439240 | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases ... | 10/21/2008 |
| 7432274 | Acyclic nucleoside derivatives Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group ... | 10/07/2008 |
| 7429595 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4 -diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and ... | 09/30/2008 |
| 7388002 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases Compounds represented by the formula: A is (CH2)nR2, —CH═CH2, CH2—CH═CH2, O(CH2)nR2, CH(OH)CH3, CH(OH)... | 06/17/2008 |
| 7375224 | Adenine modified silica-based catalyst, a process for the preparation and use there for the production of cyclic carbonates The present invention provides an adenine modified solid, ordered, mesoporous, bifunctional, organo-inorganic silica-based catalyst, its method of preparation and also a process for the production of cyclic carbonates of the formula hereinbelow | 05/20/2008 |
| 7371857 | Synthesis for hydroxyalkylated heterocyclic bases A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.... | 05/13/2008 |
| 7355043 | Preparation of purines A process for the preparation of a compound of formula (A) wherein: X is hydrogen or hydroxy, chloro, C1-6 alkoxy or pheny C1-6 alkoxy; and Ra and Rb are hydrogen, or acyl or phosphate derivatives thereof, which process co... | 04/08/2008 |
| 7351807 | Cyanine-sulfenates for dual phototherapy Dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds comprise sulfenates having the formula, t,0080 where E is selected from the group consisting of somatostatin receptor binding molecules, heat se... | 04/01/2008 |
| 7342021 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 03/11/2008 |
| 7338774 | Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same A method for determining the activity of a cell cycle regulatory factor comprising the steps of: preparing a sample for measuring a cyclin-dependent kinase/cyclin complex from living cells; reacting adenosine 5′-... | 03/04/2008 |
| 7335654 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/26/2008 |
| 7332486 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/19/2008 |
| 7321035 | Process for producing 2,6-dihalogenopurine A process for conveniently and efficiently preparing a 2,6-dihalogenopurine using an inexpensive starting material. A process for preparing a 2,6-dihalogenopurine, comprising treating a 2-amino-6-halogenopurine having a protective group at 7th position or... | 01/22/2008 |
| 7319101 | COMT inhibitors for the treatment of depression and impaired cognition The present invention relates to compounds of formula I wherein R1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the ph... | 01/15/2008 |
| 7314871 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension The application claims a method for treating hypertension by administering an effective amount of a compound of the formula (I) wherein the variable groups are as defined in the specification and claims. These 2-... | 01/01/2008 |
| 7312326 | Fluorescent labeled nucleotide derivatives Fluorescent labeled reporter compounds having a modified cyanine dye that is coupled to a nucleotide derivative through a linker are disclosed. The compounds are useful for nucleic acid sequence analysis. The fluorescent labeled reporter compounds are ring-locked cy... | 12/25/2007 |
| 7309497 | Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients The invention relates to novel pharmaceutical compositions for the systemic administration of pharmacologically active ingredients. The invention relates in particular to an injectable pharmaceutical composition comprising (a) a pharmacologically active ingredient i... | 12/18/2007 |
| 7300923 | Partial and full agonists of A1 adenosine receptors Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infa... | 11/27/2007 |
| 7291623 | Compounds that interact with kinases A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereo... | 11/06/2007 |
| 7279483 | Famciclovir monohydrate Famciclovir monohydrate and its pharmaceutical use. ... | 10/09/2007 |
| 7279482 | Heterocyclic compound based on N-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds Heterocyclic derivatives based on N6-substituted adenine of, e.g.,a formula: wherein R2 is hydrogen, R6 is R6′-X, X is —NH—, and R6′ is substituted phenyl or substituted benzyl. The derivatives... | 10/09/2007 |
| 7273864 | Compositions and methods for inducing osteogenesis The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage, using compounds of the following formula: wherein R4 ... | 09/25/2007 |
| 7273869 | Inhibitors of Akt activity The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this inven... | 09/25/2007 |
| 7271157 | Aadenosine receptor agonists Disclosed is a synthesis suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonist having the structure of Formula I: wherein R is optionally subst... | 09/18/2007 |
| 7265111 | Adenosine analogues and their use as pharmaceutical agents The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are indepe... | 09/04/2007 |
| 7262176 | Adenosine A receptor agonists Disclosed are novel compounds that are A3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia. ... | 08/28/2007 |
| 7259157 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. ... | 08/21/2007 |
| 7259159 | Guanidino derivatives as inhibitors of cell adhesion The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds o... | 08/21/2007 |
| 7256196 | Purine cytokine inhibitors The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions c... | 08/14/2007 |
| 7253154 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which m... | 08/07/2007 |
